 |
200 Diseases |  |
191 Trials |
|
191 Trials |  |
19827 News |  |
| «12...192193194195196197198199200201202203204» |
- ||||||| Humira (adalimumab) / AbbVie
Trial completion: DORA: Efficacy Study of an Anti-Tumor Necrosis Factor (TNF) Alpha Agent in Patients With Hand Osteoarthritis (clinicaltrials.gov) - Jul 24, 2012
P3, N=84, Completed, Sponsor: Assistance Publique - H
Active, not recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Enrollment closed, IO biomarker: Mechanism of Action Study for Psoriasis (clinicaltrials.gov) - Jul 19, 2012
P4, N=33, Active, not recruiting, Sponsor: Tufts Medical Center
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: Safety and Efficacy Study of Adalimumab in the Treatment of Plaque Psoriasis (clinicaltrials.gov) - Jul 18, 2012
P3, N=425, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- | Humira (adalimumab) / Eisai, AbbVie
New P4 trial: An Open-Label, Prospective Study to Assess the Safety and Effectiveness of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in the Russian Federation (clinicaltrials.gov) - Jul 17, 2012
P4, N=50, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: PIONEER (OLE): Open-label Study of the Safety and Efficacy of Adalimumab in the Treatment of Hidradenitis Suppurativa (clinicaltrials.gov) - Jul 8, 2012
P3, N=540, Enrolling by invitation, Sponsor: AbbVie (prior sponsor, Abbott)
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change: INTASAH: Intestinal Inflammation in Ankylosing Spondylitis and the Effects of Adalimumab on Mucosal Healing (clinicaltrials.gov) - Jul 5, 2012
P4, N=30, Recruiting, Sponsor: Regionshospitalet Silkeborg
Recruiting --> Active, not recruiting N=25 --> 30
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion: HECTHOR: Humira to Spare Steroids in Giant Cell Arteritis (clinicaltrials.gov) - Jul 5, 2012
P3, N=69, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
N=25 --> 30 Active, not recruiting --> Completed
- |||| Humira (adalimumab) / AbbVie
Enrollment open: Adalimumab-psoriasis and Small Bowel Lesions (clinicaltrials.gov) - Jun 28, 2012
P4, N=100, Recruiting, Sponsor: Innovaderm Research Inc.
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change, Adherence: Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab (clinicaltrials.gov) - Jun 26, 2012
P=N/A, N=7, Completed, Sponsor: Wake Forest University
Not yet recruiting --> Recruiting N=20 --> 7
- Humira (adalimumab) / Eisai, AbbVie
Trial completion, Adherence: Nurse Education in Subjects With Psoriasis Undergoing Treatment With Adalimumab (clinicaltrials.gov) - Jun 26, 2012
P=N/A, N=7, Completed, Sponsor: Wake Forest University
N=20 --> 7 Recruiting --> Completed
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: POPART: Adalimumab for the Management of Post-operative Crohn's Disease (CD) (clinicaltrials.gov) - Jun 25, 2012
P3, N=100, Not yet recruiting, Sponsor: Tel-Aviv Sourasky Medical Center
- Humira (adalimumab) / AbbVie
Trial initiation date: Vascular Inflammation in Psoriasis Trial (The VIP Trial) (clinicaltrials.gov) - Jun 12, 2012
P4, N=96, Recruiting, Sponsor: University of Pennsylvania
Recruiting --> Completed Initiation date: Mar 2012 --> Jul 2012
- Humira (adalimumab) / Eisai, AbbVie
Trial completion: Adalimumab for Inflammatory Osteoarthritis (clinicaltrials.gov) - Jun 11, 2012
P1/2, N=20, Completed, Sponsor: University of Alberta
Initiation date: Mar 2012 --> Jul 2012 Active, not recruiting --> Completed
- Biomarker, Enrollment open: RA-BioStop: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (clinicaltrials.gov) - Jun 11, 2012
P4, N=68, Recruiting, Sponsor: Medical University of Graz
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- Clinical: Causes of Visual Loss in Retinal Disease (clinicaltrials.gov) - Jun 5, 2012
P=N/A, N=2000, Enrolling by invitation, Sponsor: Royal Surrey County Hospital
- Humira (adalimumab) / Eisai, AbbVie
Enrollment open, Surgery: FACC: Anal Crohn Fistula Surgery (clinicaltrials.gov) - Jun 5, 2012
P=N/A, N=180, Recruiting, Sponsor: French Society of Coloproctology
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie
Enrollment change: Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease (clinicaltrials.gov) - Jun 1, 2012
P1/2, N=41, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Not yet recruiting --> Recruiting N=75 --> 41
- Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Humira (adalimumab) / AbbVie
Trial completion: Infliximab to Treat Crohn'S-like Inflammatory Bowel Disease in Chronic Granulomatous Disease (clinicaltrials.gov) - Jun 1, 2012
P1/2, N=41, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=75 --> 41 Recruiting --> Completed
- Clinical: Effect of Spacing of Anti-TNF Drugs in Ankylosing Spondylitis With Low Disease Activity (clinicaltrials.gov) - May 31, 2012
P=N/A, N=398, Recruiting, Sponsor: University Hospital, Montpellier
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial: Muscara: Doppler Evaluation in RA Patients After Adalimumab. (clinicaltrials.gov) - May 29, 2012
P4, N=120, Not yet recruiting, Sponsor: Ronald van Vollenhoven, prof.
- | New P4 trial: REDES-TNF: Evaluation of a Protocol for Dose Reduction in Patients With Spondylarthropathies and Clinical Remission With Anti-TNF (clinicaltrials.gov) - May 22, 2012
P4, N=190, Recruiting, Sponsor: Spanish Clinical Pharmacology Society
- | Biomarker, New P4 trial: RA-BioStop: Ultrasound and Withdrawal of Biological DMARDs in Rheumatoid Arthritis (clinicaltrials.gov) - May 16, 2012
P4, N=68, Recruiting, Sponsor: Medical University of Graz
- |||| Humira (adalimumab) / AbbVie
Trial completion, HEOR: Immediate Response With Adalimumab and Its Impact on Quality of Life and Other Comorbidity Factors in Patients With Moderate to Severe Plaque Psoriasis (clinicaltrials.gov) - May 10, 2012
P4, N=150, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Completed Active, not recruiting --> Completed
- ||||||| Humira (adalimumab) / Eisai, AbbVie
Trial completion, Monotherapy: PREMIER: Efficacy and Safety of Adalimumab and Methotrexate (MTX) Versus MTX Monotherapy in Subjects With Early Rheumatoid Arthritis (clinicaltrials.gov) - May 2, 2012
P3, N=799, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P4 trial: Optimization of Treatment With Adalimumab (Humira) (clinicaltrials.gov) - Apr 22, 2012
P4, N=309, Completed, Sponsor: Lawson Health Research Institute
- | Humira (adalimumab) / Eisai, AbbVie
Trial completion, Combination therapy: Adafi: Adalimumab in Combination With Ciprofloxacin/Placebo Treatment of Perianal Fistulas in Crohn's (clinicaltrials.gov) - Apr 15, 2012
P3, N=76, Completed, Sponsor: Foundation for Liver Research
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: A 24 Week Open Label Study of the Utility of Adalimumab in Active Axial Forms of Psoriatic Arthritis (clinicaltrials.gov) - Apr 1, 2012
P=N/A, N=168, Active, not recruiting, Sponsor: Instituto de Investigacion Biomedica de A Coruna
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment change: IMAgINE 2: Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806 (clinicaltrials.gov) - Mar 27, 2012
P3, N=100, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting N=130 --> 100
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: IMAgINE 2: Efficacy and Long Term Safety of Adalimumab in Pediatric Subjects Who Have Demonstrated Clinical Response in M06-806 (clinicaltrials.gov) - Mar 27, 2012
P3, N=100, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=130 --> 100 Enrolling by invitation --> Active, not recruiting
- |||||||||| Humira (adalimumab) / Eisai, AbbVie
New P3 trial: APPRECIA: Adalimumab on Preventing Post-chirurgic Recurrence on Crohn´s Disease (clinicaltrials.gov) - Mar 26, 2012
P3, N=84, Active, not recruiting, Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
- || Humira (adalimumab) / Eisai, AbbVie
New P3 trial: ADACAL: Assessment of Mucosal Activity to Improve the Prognosis of Patients With Crohn's Disease Treated With Immunosuppressants (clinicaltrials.gov) - Mar 22, 2012
P3, N=160, Recruiting, Sponsor: Grupo Espanol de Trabajo en Enfermedad de Crohn y Colitis Ulcerosa
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P2 trial: Crossover Study of Safety and Tolerability of Two Formulations of Adalimumab. (clinicaltrials.gov) - Mar 21, 2012
P2, N=64, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- Humira (adalimumab) / Eisai, AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Enrollment change: Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (clinicaltrials.gov) - Mar 15, 2012
P2, N=5, Completed, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
Enrolling by invitation --> Active, not recruiting N=12 --> 5
- Humira (adalimumab) / Eisai, AbbVie, Lucentis (ranibizumab) / Roche, Novartis
Trial completion: Intravitreal Adalimumab in Patients With Choroidal Neovascularization Secondary to Age-related Macular Degeneration (clinicaltrials.gov) - Mar 15, 2012
P2, N=5, Completed, Sponsor: Hospital Universitari Vall d'Hebron Research Institute
N=12 --> 5 Recruiting --> Completed
- Humira (adalimumab) / Eisai, AbbVie
Enrollment change: Primary UVB-311nm and Adalimumab in Psoriasis Patients (clinicaltrials.gov) - Mar 14, 2012
P=N/A, N=4, Completed, Sponsor: Medical University of Graz
Recruiting --> Completed N=10 --> 4
- ||||| Humira (adalimumab) / AbbVie
New P4 trial: Adalimumab-psoriasis and Small Bowel Lesions (clinicaltrials.gov) - Mar 14, 2012
P4, N=100, Recruiting, Sponsor: Innovaderm Research Inc.
- || Humira (adalimumab) / Eisai, AbbVie
Enrollment change: LOTOS: Documentation of Humira in Psoriasis Patients in Routine Clinical Practice (clinicaltrials.gov) - Mar 13, 2012
P=N/A, N=3000, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=10 --> 4 N=850 --> 3000
- | Humira (adalimumab) / AbbVie
New P4 trial: Vascular Inflammation in Psoriasis Trial (The VIP Trial) (clinicaltrials.gov) - Mar 11, 2012
P4, N=96, Recruiting, Sponsor: University of Pennsylvania
- |||||||||| Humira (adalimumab) / AbbVie
New P3 trial, HEOR: A Study to Evaluate the Impact of Adalimumab on Quality of Life, Health Care Utilization and Costs of Ulcerative Colitis Subjects in the Usual Clinical Practice Setting (clinicaltrials.gov) - Mar 8, 2012
P3, N=455, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
- ||||| Enbrel (etanercept) / Pfizer, Amgen
New P4 trial: Etanercept Treatment in Patients With Moderate to Severe Plaque Psoriasis Who Lost Response to Adalimumab (clinicaltrials.gov) - Feb 29, 2012
P4, N=100, Recruiting, Sponsor: Amgen
- | Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: A Study of the Efficacy and Safety of Adalimumab in Pediatric Subjects With Enthesitis Related Arthritis (clinicaltrials.gov) - Feb 28, 2012
P3, N=45, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
N=850 --> 3000 Recruiting --> Active, not recruiting
- Humira (adalimumab) / Eisai, AbbVie
Trial completion: Predictors of the Response to Adalimumab in Rheumatoid Arthritis (clinicaltrials.gov) - Feb 7, 2012
P4, N=200, Completed, Sponsor: University Hospital, Rouen
Recruiting --> Active, not recruiting Recruiting --> Completed
- Humira (adalimumab) / AbbVie
Trial completion: A Study of Adalimumab to Treat Sarcoidosis of the Skin (clinicaltrials.gov) - Feb 4, 2012
P2, N=16, Completed, Sponsor: Pariser, Robert J., M.D.
Recruiting --> Completed Recruiting --> Completed
- |||| Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
Combination therapy: Safety and Tolerability of Rituxan With Methotrexate and Etanercept or Methotrexate and Adalimumab in Patients With Active Rheumatoid Arthritis (clinicaltrials.gov) - Feb 1, 2012
P2, N=54, Completed, Sponsor: Biogen Idec
Recruiting --> Completed Active, not recruiting --> Completed
- Humira (adalimumab) / AbbVie
Enrollment open: CASTIP: The Influence of Adalimumab on Cardiovascular and Metabolic Risk in Psoriasis (clinicaltrials.gov) - Jan 18, 2012
P4, N=66, Recruiting, Sponsor: Medical University of Vienna
Active, not recruiting --> Completed Not yet recruiting --> Recruiting
- | Remicade (infliximab) / Merck (MSD), Mitsubishi Tanabe, J&J, Pneumovax 23 (23-valent pneumococcal polysaccharide) / Merck (MSD), Humira (adalimumab) / Eisai, AbbVie
New P4 trial, Pneumococcal vaccines: Efficacy Study of Pneumococcal Vaccination in Crohn's Disease (clinicaltrials.gov) - Jan 5, 2012
P4, N=172, Recruiting, Sponsor: Kyunghee University Medical Center
- ||||| Humira (adalimumab) / Eisai, AbbVie
Enrollment closed: Study of Adalimumab in Participants With Peripheral Spondyloarthritis (SpA) (clinicaltrials.gov) - Jan 3, 2012
P3, N=154, Active, not recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting
- ||||| Humira (adalimumab) / Eisai, AbbVie
New P2 trial: A Crossover Study of the Safety and Tolerability of Two Formulations of Adalimumab (clinicaltrials.gov) - Dec 28, 2011
P2, N=61, Completed, Sponsor: AbbVie (prior sponsor, Abbott)
- ||| Humira (adalimumab) / Eisai, AbbVie
Enrollment open: Effectiveness of Adalimumab in Moderate to Severe Plaque Psoriasis Patients With Distinct Co-morbidities (clinicaltrials.gov) - Dec 27, 2011
P=N/A, N=266, Recruiting, Sponsor: AbbVie (prior sponsor, Abbott)
Recruiting --> Active, not recruiting Not yet recruiting --> Recruiting
- | Cimzia (certolizumab pegol) / Astellas, UCB
New P4 trial: Study to Assess the Short- and Long-term Efficacy of Certolizumab Pegol Plus Methotrexate Compared to Adalimumab Plus Methotrexate in Subjects With Moderate to Severe Rheumatoid Arthritis (RA) Inadequately Responding to Methotrexate (clinicaltrials.gov) - Dec 26, 2011
P4, N=892, Active, not recruiting, Sponsor: UCB Pharma SA